PARP inhibitors are an emerging treatment option for metastatic castration-resistant prostate cancer and the 2023 ASCO Genitourinary Cancers Symposium saw initial analyses and updates from several trials of these agents that help to address some gaps in the current understanding.
In this episode, Dr. Elena Castro takes us through the latest evidence for PARP inhibitors and their combinations in this setting.
02:44 TRITON3 update
05:59 TALAPRO-2 first results
09:50 MAGNITUDE updates
13:30 PROpel OS results
16:00 Key clinical takeaways
18:26 Future perspectives
« Previous episode: How do doctors learn in the digital age?